This record was last updated July 29, 2026 (before its estimated August 11, 2026 completion). Its status may not reflect the trial's current state.
Summary
It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breast cancer.
Protocol Amendment History
6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-07-15; most recent amendment 2026-06-23.
Status change: Not Yet Recruiting → Recruiting2025-11-26